Your Partners in Unlocking New Possibilities. Meet Our Leadership Team at CPHI Frankfurt at Booth No. 5.0C84.
Book a Meeting
Your Partners in Unlocking New Possibilities. Meet Our Leadership Team at CPHI Frankfurt at Booth No. 5.0C84.
Book a Meeting
.png)
Oral Solid Dosage (OSD) forms – such as tablets and capsules – remain the backbone of modern pharmaceuticals. They are stable, scalable, and preferred by patients for their convenience and ease of administration.
Oct 28, 2025
.png)
For decades, Contract Development and Manufacturing Organizations (CDMOs) have been valued primarily for their expertise in chemistry and processes, alongside specialized skills in scale-up, synthesis, and compliance. But as the pharmaceutical landscape becomes increasingly complex and patient-centered, the expectations placed on CDMOs are rapidly evolving.
Oct 24, 2025
.png)
In the race to bring new therapies to market, active pharmaceutical ingredient (API) development is often where timelines are made or lost. Efficient synthesis, scalability, and regulatory readiness all hinge on one critical step: identifying the most effective route of synthesis.
Oct 16, 2025
.png)
Antibody-Drug Conjugates (ADCs) have rapidly emerged as one of the most promising therapeutic classes in pharmaceuticals, particularly in oncology. By combining the targeting power of monoclonal antibodies (mAbs) with the potency of cytotoxic payloads, ADCs offer precision treatment options with reduced off-target effects.
Oct 13, 2025
.png)
Peptides are short chains of amino acids that play a natural role in many biological processes. In recent years, they have become an increasingly important class of therapeutics due to their specificity, versatility, and low toxicity. As a result, peptide APIs are now at the center of modern drug discovery and development.
Oct 01, 2025
.png)
-1.png)
-1.png)
-1.png)
.png)
.png)
.png)
.png)
-1.png)
.png)
.png)
.png)
